NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…
Search results for: methotrexate
Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.
Management of Adults with JIA: Uveitis, MAS & More
Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.
In the Thick of It: Scleroderma Update 2021
Laura Hummers, MD, MSc, provided an update on the extra-pulmonary manifestations of scleroderma & the best ways to approach management of these issues.
From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management
During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, provided an update on idiopathic inflammatory myopathy.
Joint Venture: 2021 Updates in Rheumatoid Arthritis
An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.
Eye-Opening Experiences: Tips from a Rheumatology-Ophthalmology Clinic
At ACR Convergence 2021, two doctors provided an overview of inflammatory eye disease and the overlap with systemic rheumatic illnesses.
Reproductive Health & PsA: New ACR Training Program Enhances Provider Education
The ACR has developed educational materials for healthcare providers to use to discuss reproductive health and contraception with their patients with psoriatic arthritis.
Clinical Rheumatology Year in Review 2021
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy
A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 105
- Next Page »